Isogenica specialises in providing protein engineering services to pharmaceutical and biotechnology companies. Isogenica’s core drug discovery platform, “CIS display”, offers rapid discovery, identification & design of new peptide, polypeptide and antibody lead compounds. CIS display can quickly construct polypeptide libraries of unprecedented size (>10^13) and complexity in vitro, without the need for cloning. CIS display has provided hits and information against a wide range of targets and has advantages over alternative technologies. The technology is adaptable for the display of different proteins and licences are available for scFv & other polypeptide scaffolds. The technology is available for non-exclusive licensing in defined fields of research, or available under fee for service.
